The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

• ClinicalTrials.gov Identifier: NCT02921386
• Recruitment Status: Completed
• First Posted: October 3, 2016
• Results First Posted: April 12, 2018
• Last Update Posted: May 17, 2018
• Sponsor: Clarus Therapeutics, Inc.
• Collaborator: Celerion
• Information provided by (Responsible Party): Clarus Therapeutics, Inc.

Study Description

Brief Summary:

A Phase 2, open-label, randomized, cross-over, pharmacokinetic study designed to determine the effect of meals of various amounts of fat given immediately prior to dosing on the pharmacokinetics of oral testosterone undecanoate. Approximately 20 hypogonadal subjects will be dosed for a 14 day run-in period. This will be followed by a randomized sequence of five periods over a 6 day confinement period. Subjects will receive a randomly ordered sequence of breakfast meals containing various amounts of fat, fasting, 15 g, 30 g, 45 g and a high fat breakfast consistent Guidance for Industry on Food-Effect Bioavailability and Fed Bioequivalence Studies.

Condition or disease	Intervention/treatment	Phase
Hypogonadism	Drug: Oral Testosterone Undecanoate	Phase 2

Detailed Description:

This is a Phase 2, open-label, randomized, cross over, pharmacokinetic study. Subjects will initially be dosed for 2 weeks (Run-In Phase) to allow suppression of endogenous testosterone production, while allowing the oral TU to reach steady state. The subjects will then be confined to a clinical unit in which they undergo the PK Phase of the study. During the PK Phase of the study, subjects will undergo a five-period cross-over in which oral TU is dosed twice daily. Subjects will dose in the morning and in the evening immediately prior to protocol-defined meals. The protocol-defined breakfasts will contain various levels of fat including 15 g, 30 g, 45 g, a breakfast consistent with the fat and calorie content of the high-fat breakfast consistent with recommendations in the Guidance for Industry on Food-Effect Bioavailability and Fed Bioequivalence Studies (December 2002), or while fasting (with no meal until 4 hours post-dose). Subjects will be randomized to a designated sequence of the protocol-defined breakfasts, or the fasted state. The subjects will be required to consume the entire breakfast within 20 minutes during the PK Phase. The protocol-defined evening meal will be required to be consumed within 20 minutes. The 5 meal periods will occur on sequential days.

Approximately twenty (20) subjects will be enrolled in order to ensure completion of 16 subjects.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 18 participants
• Allocation: Non-Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Open-label, randomized, 5-period crossover food effect study
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate
• Study Start Date: October 2016
• Actual Primary Completion Date: January 21, 2017
• Actual Study Completion Date: January 21, 2017

Arms and Interventions

Arm	Intervention/treatment
Breakfast A - Fasting; Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.	Drug: Oral Testosterone Undecanoate; All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Breakfast B - 15 g fat; Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.	Drug: Oral Testosterone Undecanoate; All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Breakfast C - 30 g fat; Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.	Drug: Oral Testosterone Undecanoate; All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Breakfast D - 45 g fat; Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.	Drug: Oral Testosterone Undecanoate; All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Breakfast E - High Fat; Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.	Drug: Oral Testosterone Undecanoate; All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods

Outcome Measures

Primary Outcome Measures :

1. Cmax-am for Oral TU Across Breakfast With Varying Fat Content [ Time Frame: 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose ]
   Peak Concentration after morning dose (Cmax) for oral testosterone undecanoate taken after a fasting breakfast of varying fat content.
2. Time of Peak Concentration (Tmax-am) [ Time Frame: 12 hours ]
   The time of peak concentration (Tmax-am) will be assessed within each relevant dosing interval.
3. Area Under the Curve (AUC-am) [ Time Frame: 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose ]
   The 12 hours following morning dose area under the curve (AUC) will assessed for each sequence of breakfasts with varying fat content.
4. Time Weighted Average Total Testosterone Concentration (Cavg-am) [ Time Frame: 12 hours ]
   The time weighted average of total testosterone concentration will be assessed for each dosing interval.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Man 18 to 65 years of age, inclusive, with a clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism for testosterone naïve subjects and history of signs/symptoms for subjects who have received prior treatment) as well as testosterone levels consistent with hypogonadism as defined by 2 morning total T values of <300 ng/dL (between 6:00 and 10:00 AM drawn on 2 separate days [approximately 7 (±2) days apart].
2. Adequate venous access in the left or right arm to allow collection of a number of blood samples via a venous cannula.
3. Must be naïve to androgen-replacement therapy or washed out of prior androgen replacement therapies; that is, be willing to cease current T treatment or currently not be taking T treatment, (washout durations specified in exclusion criterion #1). Subjects must remain off all forms of T, except for dispensed study drug, throughout the entire study.
4. Subjects on replacement therapy for hypopituitarism or multiple endocrine deficiencies must be on stable doses of thyroid hormone and adrenal replacement hormones for at least 14 days before Screen 1.
5. Has voluntarily given written informed consent to participate in this study.

Exclusion Criteria:

1. Received oral topical (eg, gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (eg, T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (eg, AVEED) within the previous 20 weeks, or T implantable pellets (Testopel®) within the previous 6 months.
2. Has an intercurrent disease deemed clinically significant in the opinion of the investigator of any type; in particular, liver, kidney, uncontrolled or poorly controlled heart disease, including hypertension, congestive heart failure or coronary heart disease, or psychiatric-illness, including severe depression.
3. Has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.
4. Has a mean of the triplicate assessment of sBP > 150 mm Hg and/or dBP > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water). Subjects < 60 years of age and prescribed antihypertensives will be excluded if the mean of the triplicate assessment of sBP > 140 mm Hg and/or dBP > 90 mm Hg at screening.
5. Has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
6. Has untreated, severe obstructive sleep apnea.
7. Has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN and serum creatinine > 1.5 × ULN.
8. Has a hematocrit (HCT) value of < 35% or > 48%.
9. Has a history of polycythemia, either idiopathic or associated with TRT treatment.
10. Is a diabetic subject with a glycosylated hemoglobin > 8.5%.
11. Has a body mass index (BMI) ≥ 38 kg/m2.
12. Has been on stable doses of antihypertensive medication for < 3 months.
13. Has an abnormal prostate digital rectal examination [(DRE); palpable nodules], elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening, and/or history of, or current or suspected, prostate cancer.
14. Has a history of, or current or suspected, breast cancer.
15. Has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.
16. Use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.
17. Has known malabsorption syndrome and/or current treatment with oral lipase inhibitors (eg, orlistat [Xenical®]) and/or bile acid-binding resins (eg, cholestyramine [Questran®], colestipol [Colestid®]) or treatments that promote gastric emptying (eg, metoclopramide [Reglan®]).
18. Inability to observe all rules and smoking restrictions in place at the clinical facility during confinement.
19. Has history of abuse of alcohol or any drug substance within the previous 2 years.
20. Poor compliance or unlikely to keep clinic appointments and remain for entire confinement period.
21. Has received any drug as part of another research study within 30 days of initial dose administration in this study.
22. Donated blood (≥ 500 mL) within the 12-week period before the initial study dose.
23. Current use of the following groups of drugs that effect T levels, T metabolism or levels of T metabolites, namely antiandrogens, 5-alpha-reductase inhibitors (eg, dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone hydrochloride, buprenorphine hydrochloride) or human growth hormone (HGH).
24. Unwilling or unable to follow the dietary requirements for this study.

Contacts and Locations

Locations

United States, California

Harbor-UCLA Medical Center

Torrance, California, United States, 90502

United States, Florida

Orlando Clinical Research Center

Orlando, Florida, United States, 32809-3017

Sponsors and Collaborators

Clarus Therapeutics, Inc.

Celerion

Investigators

• Principal Investigator: Ronald Swerdloff; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

  Study Documents (Full-Text)

Documents provided by Clarus Therapeutics, Inc.:

Study Protocol  [PDF] September 15, 2016

Statistical Analysis Plan  [PDF] March 23, 2017

More Information

• Responsible Party: Clarus Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT02921386
• Other Study ID Numbers: CLAR-16015
• First Posted: October 3, 2016
• Results First Posted: April 12, 2018
• Last Update Posted: May 17, 2018
• Last Verified: April 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Hypogonadism; Gonadal Disorders; Endocrine System Diseases; Methyltestosterone; Testosterone; Testosterone undecanoate; Testosterone enanthate; Testosterone 17 beta-cypionate; Androgens; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Anabolic Agents